Carisma Therapeutics Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD from Q4 2021 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Carisma Therapeutics Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax history and growth rate from Q4 2021 to Q4 2023.
  • Carisma Therapeutics Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending December 31, 2023 was $0.000.
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $0 +$41K Dec 31, 2023 10-K 2024-04-01
Q3 2023 $373K +$608K Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $265K +$546K Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $136K Mar 31, 2023 10-Q 2023-05-11
Q4 2022 -$41K -$41K Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$235K Sep 30, 2022 10-Q 2022-11-07
Q2 2022 -$281K Jun 30, 2022 10-Q/A 2022-08-25
Q4 2021 $0 Dec 31, 2021 10-K 2023-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.